Chugai Pharmaceutical (OTCMKTS:CHGCY) vs. Nanobiotix (NASDAQ:NBTX) Head-To-Head Review

Chugai Pharmaceutical (OTCMKTS:CHGCY) and Nanobiotix (NASDAQ:NBTX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings.

Analyst Ratings

This is a summary of current recommendations and price targets for Chugai Pharmaceutical and Nanobiotix, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chugai Pharmaceutical	0	1	1	2	3.25
Nanobiotix	1	1	4	0	2.50

Nanobiotix has a consensus target price of $37.33, indicating a potential downside of 0.86%. Given Nanobiotix’s higher possible upside, analysts plainly believe Nanobiotix is more favorable than Chugai Pharmaceutical.

Profitability

This table compares Chugai Pharmaceutical and Nanobiotix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Chugai Pharmaceutical	35.09%	23.71%	19.96%
Nanobiotix	N/A	N/A	N/A

Risk and Volatility

Chugai Pharmaceutical has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500. Comparatively, Nanobiotix has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500.

Earnings and Valuation

This table compares Chugai Pharmaceutical and Nanobiotix”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chugai Pharmaceutical	$8.41 billion	8.38	$2.91 billion	$0.92	23.27
Nanobiotix	$29.64 million	64.31	-$27.11 million	N/A	N/A

Chugai Pharmaceutical has higher revenue and earnings than Nanobiotix.

Institutional & Insider Ownership

0.0% of Chugai Pharmaceutical shares are held by institutional investors. Comparatively, 38.8% of Nanobiotix shares are held by institutional investors. 3.5% of Nanobiotix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Chugai Pharmaceutical beats Nanobiotix on 7 of the 13 factors compared between the two stocks.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

About Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.